Research / ANG-PD / Fundamental state Inspectable configuration
State dimensions Filing 0001039828-20-000041 Insurance
Cash 95th Own-history percentile · N=20
Evidence method Level · gp.fundamentals.cash
$1.8B · CORE · VALID
Premium growth 95th Own-history percentile · N=20
Evidence method Yoy · gp.insurance.premiums
41.66% · CORE · VALID
Revenue growth 0th Own-history percentile · N=20
Evidence method Yoy · gp.fundamentals.revenue
-132.35% · CORE · VALID
As-filed lineage Fundamental state history Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History 51 states Self-history eligible
Sep 30, 2021 4/4 normalized Level 3 Dec 31, 2021 4/4 normalized Level 3 Mar 31, 2022 4/4 normalized Level 3 Jun 30, 2022 3/3 normalized Level 3 Sep 30, 2022 4/4 normalized Level 3 Dec 31, 2022 4/4 normalized Level 3 Mar 31, 2023 4/4 normalized Level 3 Jun 30, 2023 4/4 normalized Level 3 Sep 30, 2023 4/4 normalized Level 3 Dec 31, 2023 4/4 normalized Level 3 Mar 31, 2024 3/3 normalized Level 3 Jun 30, 2024 4/5 normalized Level 3 Sep 30, 2024 4/5 normalized Level 3 Dec 31, 2024 4/5 normalized Level 3 Mar 31, 2025 4/5 normalized Level 3 Jun 30, 2025 5/6 normalized Level 3 Sep 30, 2025 4/5 normalized Level 3 Dec 31, 2025 5/6 normalized Level 3 Mar 31, 2026 4/5 normalized Level 3 Jun 30, 2026 6/6 normalized Level 4 Period transition
What moved in the state? Cash Decreased
Previous $2.3B
Current $1.8B
Delta -$460.3M Premium Growth Increased
Previous -11.13%
Current 41.66%
Delta 52.79% Revenue Growth Decreased
Previous 123.93%
Current -132.35%
Delta -256.27% Self-history only Previous similar states Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.